Literature DB >> 2467131

Pharmacokinetics of amlodipine in renal impairment.

M S Laher1, J G Kelly, G D Doyle, M Carmody, J F Donohoe, H Greb, M Volz.   

Abstract

The pharmacokinetics of amlodipine was studied in 27 subjects with renal function ranging from normal to dialysis-dependent. Amlodipine (as a single 5-mg capsule) was administered once daily for 14 days and its plasma concentrations were measured by gas chromatography during and after treatment. Renal impairment had little or no effect on the pharmacokinetics of amlodipine. The elimination half-life was of the order of 50 h, similar to previously observed values, and did not vary with differences in renal function. Steady-state predose concentrations were observed after the ninth dose. Accumulation of amlodipine to steady-state levels was not significantly different from that expected on theoretical grounds and did not significantly change with renal function. These results suggest that once-daily administration of amlodipine is suitable for all degrees of renal function and that dosage adjustment is not necessary in renal impairment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2467131     DOI: 10.1097/00005344-198812007-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 3.  A review of calcium channel antagonists in the treatment of pediatric hypertension.

Authors:  Shobha Sahney
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis.

Authors:  G Kungys; H Naujoks; C Wanner
Journal:  Eur J Clin Pharmacol       Date:  2003-07-04       Impact factor: 2.953

Review 5.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

7.  Antianginal effects of amlodipine at a single dose on exertional angina patients using treadmill exercise testing--a randomized crossover study in comparison with placebo.

Authors:  H Kishida; N Hata; T Kunimi; H Miyagawa; H Nishiyama; K Katoh
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

8.  Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.

Authors:  Dwaipayan Mukherjee; Jiuhong Zha; Rajeev M Menon; Mohamad Shebley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-09       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.